OncLive TV

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.

Jeffrey S. Weber, MD, PhD, discusses the evolution of the treatment paradigm in melanoma.

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.

Monica L. Baskin, PhD, discusses the roles of race and early screening in prostate cancer.

Brian T. Hill, MD, PhD, discusses the approval of brexucabtagene autoleucel  in mantle cell lymphoma.

Ira Braunschweig, MD, discusses factors to consider when selecting between autologous stem cell transplant, allogeneic stem cell transplant, and CAR T-cell therapy in diffuse large B-cell lymphoma.

Ramaprasad Srinivasan, MD, PhD, discusses the challenges of developing new therapies to treat patients with rare renal cell carcinoma subtypes.

Jason J. Luke, MD, FACP, discusses the role of targeted therapy in melanoma.

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

William D. Tap, MD, discusses future research efforts in sarcoma.

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.

Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.

Sagar Lonial, MD, FACP, discusses the role of BCMA ​as a target in multiple myeloma.

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men. 

Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.

Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.

Nilofer S​aba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

William D. Tap, MD, discusses the importance of ​community and academic collaboration in sarcoma.